Kolkata/IBNS, Jan. 8 -- Shares of Panacea Biotec Ltd. surged around 9 per cent on Thursday after the pharmaceutical and vaccine maker announced the completion of enrollment for the Phase III clinical trial of its dengue vaccine candidate, DengiAll, media reports said.

Under the study protocol, each participant will be monitored for a period of two years after receiving either the vaccine or a placebo to assess the efficacy, safety and immunogenicity of the candidate.

DengiAll is a live-attenuated tetravalent dengue vaccine designed to provide protection against all four dengue virus serotypes.

The ongoing Phase III trial is aimed at evaluating the vaccine's safety, immunogenicity and efficacy in the Indian population, with long-term fo...